中文

Hong Kong Stocks · Free Data Page

KEYMED BIO-B 02162

KEYMED BIO-B: FY2025 revenue CN¥716.3M (+67.30% YoY); net income -CN¥522.6M; 2 alerts, 0 watch items out of 17 risk checks; no TTM dividend.
Close PriceHK$68.45Day +7.88%Market CapHK$20.45BP/E22.5xTTMP/B4.43xROE (FY2025)-19.9%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for KEYMED BIO-B?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2019–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Net income was negative in FY2019, FY2020, FY2021, FY2022, FY2023, FY2024, FY2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)0.110.100.350.430.72
YoY—-9.3%253.9%20.9%67.3%
Net Income (CNY B)-3.89-0.31-0.36-0.52-0.52
Operating Cash Flow (CNY B)-0.21-0.40-0.30-0.79-0.71
ROE-106.5%-8.8%-11.4%-18.9%-19.9%
Gross Margin84.4%97.4%89.6%97.2%87.7%
Net Margin-3525.3%-307.9%-101.5%-120.3%-73.0%
Debt-to-Assets7.3%15.1%23.1%34.3%34.2%
Show all 7 fiscal years
Fiscal Year2019202020212022202320242025
Revenue (CNY B)—0.000.110.100.350.430.72
YoY———-9.3%253.9%20.9%67.3%
Net Income (CNY B)-0.17-0.82-3.89-0.31-0.36-0.52-0.52
Operating Cash Flow (CNY B)-0.07-0.12-0.21-0.40-0.30-0.79-0.71
ROE——-106.5%-8.8%-11.4%-18.9%-19.9%
Gross Margin——84.4%97.4%89.6%97.2%87.7%
Net Margin——-3525.3%-307.9%-101.5%-120.3%-73.0%
Debt-to-Assets—306.6%7.3%15.1%23.1%34.3%34.2%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

2Alert 0Watch 13Pass 2N/A

Items Flagged for Review

  • Alert

    Interest CoverageSolvency

    Negative (negative EBIT)

    FY2025 (ended 2025-12-31) · What is this?

  • Alert

    Net LossesGoing Concern

    FY2025 (2025-12-31) CN¥-0.52B, FY2024 (2024-12-31) CN¥-0.52B

    FY2025 (ended 2025-12-31)

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

No dividends paid over the trailing 12 months.

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.